Table 2 Outcome characteristics of patients: entire cohort and subgroups (main treatment indications)
From: Overview of the current use of levosimendan in France: a prospective observational cohort study
Patient characteristics | All patients (n = 602) | Cardiogenic shock (n = 250) | Decompensated heart failure (n = 127) | Cardiac surgery-relateda (n = 86) | Weaning from ECMO (n = 82) | P-value |
|---|---|---|---|---|---|---|
Hypotension after levosimendan | 218 (36.2%) | 108 (43.2%) | 42 (33.1%) | 25 (29.1%) | 24 (29.3%) | 0.05 |
Atrial fibrillation after levosimendan | 85 (14.1%) | 45 (18%) | 13 (10.2%) | 12 (13.9%) | 14 (17.1%) | 0.01 |
Serious adverse events after levosimendan | 14 (2.3%) | 10 (4%) | 1 (0.8%) | 2 (2.3%) | 0 | 0.19 |
Length of Intensive Care Unit stay (days)b | 15 [7–27] | 16 [8–30] | 10 [4–21] | 12 [7–21] | 22 [18–36] | < 0.001 |
Length of hospital stay (days)b | 23.5 [13–44] | 23 [13–42] | 16 [10–33] | 22 [14–34] | 34 [18–53] | 0.002 |
In-hospital mortality | 136 (22.6%) | 66 (26.4%) | 21 (16.5%) | 10 (11.6%) | 34 (41.5%) | < 0.001 |
Mortality during follow-up | 26 (4.3%) | 9 (3.6%) | 7 (5.5%) | 2 (2.3%) | 0 | 0.001 |